Teva Pharmaceutical Industries signed a global licensing agreement with Polpharma Biologics for a biosimilar candidate to Ocrevus. This treatment targets multiple sclerosis. Teva gains exclusive commercialization rights in major markets. Polpharma will manage development and manufacturing, while Teva handles regulatory submissions and commercialization.
The company is advancing its anti-IL-15 antibody, TEV-408, into a Phase 2b trial for vitiligo. Teva also submitted a New Drug Application to the U.S. FDA for ecopipam. This drug is a potential first-in-class treatment for pediatric Tourette syndrome.
Teva expanded its Canadian portfolio through a commercialization agreement with Samsung Bioepis for an Eylea biosimilar. These developments align with Teva’s strategy to diversify beyond generics. The company is prioritizing high-margin biosimilars and innovative specialty medicines.